Treatment coverage for depression in the general Spanish population and the impact of the Covid-19 pandemic
Lea Francia,
Riccardo De Giorgi,
Elvira Lara,
Blanca Dolz del Castellar,
Chiara Castelletti,
Cristina Rodríguez-Prada,
Joan Domènech-Abella,
Beatriz Olaya,
Josep Maria Haro,
José Luis Ayuso Mateos
Affiliations
Lea Francia
Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, IIS Princesa, Spain; Department of Psychiatry, Faculty of Medicine, Universidad Autonoma de Madrid, Madrid, Spain; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain; Corresponding author. Department of Psychiatry, C/Arzobispo Morcillo, 4, Madrid, 28029, Madrid, Spain.
Riccardo De Giorgi
Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, X3 7JX, United Kingdom; Oxford Health NHS Foundation Trust, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, United Kingdom
Elvira Lara
Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain; Department of Personality, Evaluation and Clinical Psychology, Faculty of Psychology, Universidad Complutense de Madrid, Madrid, Spain
Blanca Dolz del Castellar
Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, IIS Princesa, Spain; Department of Psychiatry, Faculty of Medicine, Universidad Autonoma de Madrid, Madrid, Spain; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain
Chiara Castelletti
Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, IIS Princesa, Spain; Department of Psychiatry, Faculty of Medicine, Universidad Autonoma de Madrid, Madrid, Spain; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain
Cristina Rodríguez-Prada
Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, IIS Princesa, Spain; Department of Psychiatry, Faculty of Medicine, Universidad Autonoma de Madrid, Madrid, Spain; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain
Joan Domènech-Abella
Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain; Unitat de Recerca Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain
Beatriz Olaya
Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain; Unitat de Recerca Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain
Josep Maria Haro
Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain; Unitat de Recerca Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain
José Luis Ayuso Mateos
Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, IIS Princesa, Spain; Department of Psychiatry, Faculty of Medicine, Universidad Autonoma de Madrid, Madrid, Spain; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain
Background: Despite the availability of effective antidepressant strategies, numerous people with depressive disorders remain untreated. The Covid-19 pandemic has affected healthcare services, especially the mental health sector. This study aims to explore the coverage of depression treatments in the general Spanish population and the impact of the Covid-19 pandemic. Methods: We used longitudinal data (2018 and 2022) from the general Spanish population: pre-pandemic n = 1512; mean age = 65.43 years ± 14.90; 56 % females; post-pandemic n = 909; mean age = 68.00 years ± 14.24; 54 % women. The International Classification of Disease 10th edition was used to diagnose lifetime depressive episodes and severity. We explored psychological and pharmacological treatment coverage via multiple logistic regressions adjusted for 4 covariates (sex assigned at birth, education level, age, Covid-19 pandemic) for participants with a diagnosis of depression. Results: Treatment coverage for depression in the pre-pandemic and post-pandemic samples was, respectively, 53.3 % and 51.9 %. We observed an association between severe depression and treatment coverage (OR = 2.77, 95%CI 1.05 to 7.75). We found no association between the COVID-19 pandemic and treatment coverage. Conclusions: The pharmacological treatment coverage was associated with severe types of depression. The prevalence rates of treatment coverage were similar in the pre- and post-COVID-19 pandemic attesting to the resilience of the mental health system in Spain.